Fortress Biotech(FBIO) - 2023 Q4 - Annual Results

Exhibit 99.1 Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 Miami, FL – March 28, 2024 – Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmace ...